Multivariate analysis of association with graft failure
| Variable . | Regression coefficient (95% CI) . | Improvement χ2 . | P value . | Risk ratio (95% CI) . |
|---|---|---|---|---|
| First analysis | ||||
| CD3+ cells × 106/kg (≤ 0.2 vs > 0.2) | 2.8 (0.8-4.8) | 18.6 | < .0001 | 17 (2.3-126.6) |
| Diagnosis (CML vs others) | 1.1 (−0.5-2.7) | 6.4 | .01 | 2.9 (1.3-6.6) |
| Second analysis | ||||
| CD3+ cells × 106/kg (≤ 0.2 vs > 0.2) | 2.8 (0.8-4.8) | 18.6 | < .0001 | 16.9 (2.3-125) |
| CML + Bu (yes vs no) | 1.6 (0.7-2.4) | 11.3 | .001 | 4.8 (2.1-10.9) |
| Variable . | Regression coefficient (95% CI) . | Improvement χ2 . | P value . | Risk ratio (95% CI) . |
|---|---|---|---|---|
| First analysis | ||||
| CD3+ cells × 106/kg (≤ 0.2 vs > 0.2) | 2.8 (0.8-4.8) | 18.6 | < .0001 | 17 (2.3-126.6) |
| Diagnosis (CML vs others) | 1.1 (−0.5-2.7) | 6.4 | .01 | 2.9 (1.3-6.6) |
| Second analysis | ||||
| CD3+ cells × 106/kg (≤ 0.2 vs > 0.2) | 2.8 (0.8-4.8) | 18.6 | < .0001 | 16.9 (2.3-125) |
| CML + Bu (yes vs no) | 1.6 (0.7-2.4) | 11.3 | .001 | 4.8 (2.1-10.9) |
CI indicates confidence interval; CML, chronic myeloid leukemia; CML + Bu, patients diagnosed with CML and conditioned with busulphan-based regimens.